TNX-102 not checked

Tonix Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
2 active
17 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will take 5.6 mg of TNX-102 SL ( 2 x 2.8 mg TNX-102 SL tablets) daily at bedtime.”In the company’s words, NCT07621237 on ClinicalTrials.gov
Tested for
Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression, Pharmakokinetic, Open Label, Phase 1
Main trialPhase 2
“The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are: Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL? Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder. Participants will: Take TNX-102 SL or a…”In the company’s words, NCT07621237 on ClinicalTrials.gov
Other names
cyclobenzaprine · cyclobenzaprine HCl · cyclobenzaprine HCI

Other drugs for Major Depressive Disorder (MDD)

All 36 drugs for Major Depressive Disorder (MDD)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Feb 2028 A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Phase 1Active, not recruiting 10 Feb 2026 A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
Phase 3Terminated 13 Sep 2016 Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
Phase 3Completed 28 Sep 2016 A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Phase 3Completed Sep 2016 A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
Phase 3Terminated 27 Jul 2018 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
Phase 3Terminated 27 Jul 2018 Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
Phase 3Completed 30 Sep 2019 A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Phase 3Terminated 24 Apr 2020 A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
Phase 3Completed 29 Oct 2020 A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Phase 3Completed 1 Nov 2021 A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Phase 3Completed 14 Nov 2023 A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
Phase 2Completed 26 May 2016 Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
Phase 2Completed May 2016 Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
Phase 2Withdrawn 8 Nov 2022 Safety and Efficacy Study of TNX-102 SL in Participants With PTSD
Phase 2Completed 12 Jul 2023 A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
Phase 1Completed 30 Apr 2022 A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TNX-102

Following is part of Solo: you see every change to TNX-102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in